Home > Boards > US Listed > Medical - Drugs > Allergan (AGN)

FDA approves AGN’s Ubrelvy (ubrogepant) for acute migraine treatment:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 728
Posts 110,833
Boards Moderated 15
Alias Born 09/05/02
160x600 placeholder
Form 8.3 - [ AbbVie Inc.] Dow Jones News - 2/18/2020 9:51:00 AM
Form 8.3 - [Abbvie. Inc] Dow Jones News - 2/17/2020 9:12:00 AM
Announcement under the Irish Takeover Rules: Relevant Securities in Issue - February 14, 2020 PR Newswire (US) - 2/14/2020 4:15:00 PM
Form 8.3 - [Abbvie. Inc] Dow Jones News - 2/14/2020 9:23:00 AM
Announcement under Rule 8.1(a) of the Irish Takeover Rules: Dealings by Offerors, Offerees or Parties Acting in Concert With ... PR Newswire (US) - 2/14/2020 7:00:00 AM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 2/13/2020 5:14:08 PM
Davidson Kempner Capital Management LP Davidson Kempner Capital Management Lp : Form 8.3 - Allergan Plc Dow Jones News - 2/13/2020 10:50:00 AM
Form 8.3 - [Abbvie. Inc] Dow Jones News - 2/13/2020 9:56:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 11:04:08 AM
Davidson Kempner Capital Management LP Davidson Kempner Capital Management Lp : Form 8.3 - Allergan Plc Dow Jones News - 2/12/2020 10:50:00 AM
Form 8.3 - [Abbvie. Inc] Dow Jones News - 2/12/2020 10:01:00 AM
Davidson Kempner Capital Management LP Davidson Kempner Capital Management Lp : Form 8.3 - Allergan Plc Dow Jones News - 2/11/2020 10:50:00 AM
Form 8.3 -AbbVie Inc. Dow Jones News - 2/11/2020 9:54:00 AM
Davidson Kempner Capital Management LP Davidson Kempner Capital Management Lp : Form 8.3 - Allergan Plc Dow Jones News - 2/10/2020 10:50:00 AM
Form 8.3 - Abbvie Inc Dow Jones News - 2/10/2020 10:06:00 AM
Allergan Tops 4Q Forecasts For Revenue, Adjusted Profit Dow Jones News - 2/10/2020 7:46:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2020 7:36:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/10/2020 7:26:04 AM
Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results PR Newswire (US) - 2/10/2020 7:00:00 AM
Davidson Kempner Capital Management LP Davidson Kempner Capital Management Lp : Form 8.3 - Allergan Plc Dow Jones News - 2/7/2020 10:50:00 AM
Form 8.3 - [AbbVie Inc.] Dow Jones News - 2/7/2020 9:26:00 AM
Form 8.3 - [AbbVie Inc.] Dow Jones News - 2/6/2020 9:40:00 AM
Form 8.3 - [Allergan Plc] Dow Jones News - 2/5/2020 9:51:00 AM
Form 8.3 - [AbbVie Inc.] Dow Jones News - 2/5/2020 9:45:00 AM
Form 8.3 - [ AbbVie Inc.] Dow Jones News - 2/4/2020 8:49:00 AM
DewDiligence Member Level  Monday, 12/23/19 03:23:55 PM
Re: None
Post # of 198 
FDA approves AGN’s Ubrelvy (ubrogepant) for acute migraine treatment:

https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine

Ubrelvy may do well in the crowded CGRP arena because it’s oral.

AGN has a second oral CGRP candidate, Atogepant, in development for migraine prevention.

AGN acquired both drugs from MRK in 2015 for what now appears to be a very reasonable price (#msg-115206907).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist